Glycated albumin

Zendjabil, Mustapha

doi:10.1016/j.cca.2019.11.007

Cited by 62 publications

(42 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Albumin is the most abundant plasma protein, with a half-life of about 21 days, that undergoes non-enzymatic glycosylation due to its high circulating concentration, the number of lysine and arginine residues making it more prone to glycation [6,25].…”

Section: Glycated Albumin (Ga)mentioning

confidence: 99%

“…The GA test provides information on the mean blood glucose concentration in the last 15-20 days before blood collection [4,6,8,11,19,24].…”

Section: Ga Testmentioning

confidence: 99%

“…As a medium-term glycemic status indicator, GA is originally taken into consideration for the diagnosis of diabetes in patients with hemoglobinopathies and other conditions in which the measurement of HbA1c is not reliable [4,6,52,54]. It has also been assessed in screening programs to detect individuals with prediabetes [23,25].…”

Section: Ga and Diabetes Diagnosismentioning

confidence: 99%

“…Glycated Albumin (GA) [4][5][6] represent a useful tool reflecting glycemic homeostasis over a period of three weeks. GA provides a qualitatively and quantitatively significant contribution to the clinical process of screening, prediction, prevention, diagnosis, prognosis and monitoring of the metabolic disorders of several organs [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

“…GA, a unique post-translational product of the glycosylation of albumin, has been shown to be a useful biomarker in: (i) clinical conditions in which the dosage of glycated hemoglobin (HbA1c) does not reflect glycemic compensation, such as chronic renal failure, gestational diabetes, dialysis complications, hemorrhages, recent transfusions, hemolytic anemia and hemoglobin variants [6,[9][10][11][12][13]; (ii) patients with poorly controlled diabetes and with postprandial hyperglycemia in order to monitor short-term glycemic fluctuation [14,15]; (iii) diabetic patients for monitoring therapeutic response [16][17][18][19]; (iv) detecting prediabetes even in the presence of normoglycemia, which is a priority because the effectiveness of this lifestyle intervention is lost if diabetes has already developed [20,21]. It is well known that fructosamine represents all the circulating glycated proteins, therefore Glycated Albumin is biochemically recognized as a form of fructosamine [14].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Diseases

Giglio

Sasso

Agnello

et al. 2020

JCM

View full text Add to dashboard Cite

Diabetes mellitus is a heterogeneous and dysmetabolic chronic disease in which the laboratory plays a fundamental role, from diagnosis to monitoring therapy and studying complications. Early diagnosis and good glycemic control should start as early as possible to delay and prevent metabolic and cardio-vascular complications secondary to this disease. Glycated hemoglobin is currently used as the reference parameter. The accuracy of the glycated hemoglobin dosage may be compromised in subjects suffering from chronic renal failure and terminal nephropathy, affected by the reduction in the survival of erythrocytes, with consequent decrease in the time available for glucose to attach to the hemoglobin. In the presence of these renal comorbidities as well as hemoglobinopathies and pregnancy, glycated hemoglobin is not reliable. In such conditions, dosage of glycated albumin can help. Glycated albumin is not only useful for short-term diagnosis and monitoring but predicts the risk of diabetes, even in the presence of euglycemia. This protein is modified in subjects who do not yet have a glycemic alteration but, as a predictive factor, heralds the risk of diabetic disease. This review summarizes the importance of glycated albumin as a biomarker for predicting and stratifying the cardiovascular risk linked to multiorgan metabolic alterations.

show abstract

Section: Glycated Albumin (Ga)mentioning

confidence: 99%

“…The GA test provides information on the mean blood glucose concentration in the last 15-20 days before blood collection [4,6,8,11,19,24].…”

Section: Ga Testmentioning

confidence: 99%

Section: Ga and Diabetes Diagnosismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Diseases

Giglio

Sasso

Agnello

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

Communal interaction of glycation and gut microbes in diabetes mellitus, Alzheimer's disease, and Parkinson's disease pathogenesis

Patil,

Tupe

2023

Medicinal Research Reviews

View full text Add to dashboard Cite

Diabetes and its complications, Alzheimer's disease (AD), and Parkinson's disease (PD) are increasing gradually, reflecting a global threat vis‐à‐vis expressing the essentiality of a substantial paradigm shift in research and remedial actions. Protein glycation is influenced by several factors, like time, temperature, pH, metal ions, and the half‐life of the protein. Surprisingly, most proteins associated with metabolic and neurodegenerative disorders are generally long‐lived and hence susceptible to glycation. Remarkably, proteins linked with diabetes, AD, and PD share this characteristic. This modulates protein's structure, aggregation tendency, and toxicity, highlighting renovated attention. Gut microbes and microbial metabolites marked their importance in human health and diseases. Though many scientific shreds of evidence are proposed for possible change and dysbiosis in gut flora in these diseases, very little is known about the mechanisms. Screening and unfolding their functionality in metabolic and neurodegenerative disorders is essential in hunting the gut treasure. Therefore, it is imperative to evaluate the role of glycation as a common link in diabetes and neurodegenerative diseases, which helps to clarify if modulation of nonenzymatic glycation may act as a beneficial therapeutic strategy and gut microbes/metabolites may answer some of the crucial questions. This review briefly emphasizes the common functional attributes of glycation and gut microbes, the possible linkages, and discusses current treatment options and therapeutic challenges.

show abstract

Effects of Elobixibat in Patients with Diabetes and Concomitant Chronic Constipation: an 8-week, Prospective, Single-center, Single-arm Study

et al. 2022

View full text Add to dashboard Cite

Aims: To evaluate the efficacy and safety of elobixibat in patients with diabetes and concomitant chronic constipation. Methods: This was a single-center, single-arm study. Thirty-three patients with diabetes and chronic constipation, as defined by the Rome IV criteria, were treated with elobixibat (10 mg/day) for 8 weeks. Patients recorded stool properties, including spontaneous bowel movements (SBMs) and stool consistency, according to the Bristol Stool Form Scale (BSFS). Quality of life for constipation was evaluated with the Japanese version of the Patient Assessment of Constipation Quality of Life (JPAC-QOL). Results: Of the 33 eligible patients, 30 completed the study. Elobixibat significantly increased the median (interquartile range) frequency of SBMs per week, from 5.0 (3.0-7.0) at baseline to 6.0 (4.0-7.0] at week 8 (p = 0.030). After 8 weeks, the BSFS score approached 4; the score for normal stool consistency and the JPAC-QOL score significantly improved from 1.05 ± 0.40 at baseline to 0.94 ± 0.53 (p =

show abstract

Glycated albumin

Cited by 62 publications

References 67 publications

Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Diseases

Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Diseases

Communal interaction of glycation and gut microbes in diabetes mellitus, Alzheimer's disease, and Parkinson's disease pathogenesis

Effects of Elobixibat in Patients with Diabetes and Concomitant Chronic Constipation: an 8-week, Prospective, Single-center, Single-arm Study

Contact Info

Product

Resources

About